Showing results (41-50 of 88) with videos related to

Sort By:
Pageof 9
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 31, 2017
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide MaintenanceMeighan Palazzo, Gunjan L Shah, Olivia Copelan, et al.
Nature Medicine|October 2, 2023
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trialNizar J Bahlis, Caitlin L Costello, Noopur S Raje, et al.
Blood Neoplasia|July 12, 2026
CD8<sup>+</sup>CD38<sup>+</sup> T cells identify functional high-risk multiple myeloma after autologous transplant: BMT CTN 0702 correlatesNezar Mehanna, Andriy Derkach, Billel Gasmi, et al.
The New England Journal of Medicine|March 9, 2012
Immunologic correlates of the abscopal effect in a patient with melanomaMichael A Postow, Margaret K Callahan, Christopher A Barker, et al.
The New England Journal of Medicine|December 9, 2014
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphomaStephen M Ansell, Alexander M Lesokhin, Ivan Borrello, et al.
Cancer Immunology Research|March 2, 2016
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1Jarushka Naidoo, Katja Schindler, Christiane Querfeld, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 23, 2020
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple MyelomaSusan Bal, Heather J Landau, Gunjan L Shah, et al.
Blood Advances|July 11, 2019
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota compositionMatthew J Pianko, Sean M Devlin, Eric R Littmann, et al.
Blood Neoplasia|June 27, 2025
Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experienceMalin Hultcrantz, Andriy Derkach, Hani Hassoun, et al.
Blood Cancer Journal|May 27, 2024
Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myelomaBruno Almeida Costa, Jessica Flynn, Noriko Nishimura, et al.
Pageof 9